0000000000258230

AUTHOR

Alice Indini

showing 2 related works from this author

Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 count…

2022

© 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licenseBackground: The 2015 Lancet Commission on global surgery identified surgery and anaesthesia as indispensable parts of holistic health-care systems. However, COVID-19 exposed the fragility of planned surgical services around the world, which have also been neglected in pandemic recovery planning. This study aimed to develop and validate a novel index to support local elective surgical system strengthening and address growing backlogs. Methods: First, we performed an international consultation through a four-stage consensus process to develop a multidomain index for hospital-level assess…

MaleHealth system resilience.*COVID-19/epidemiologySocial SciencesSağlık BilimleriGlobal HealthFundamental Medical SciencesClinical Medicine (MED)AnaesthesiasurgeryTIP GENEL & DAHİLİnisu navedene ključne riječiElective backlogMedicine and Health SciencesTOOLKlinik Tıp (MED)610 Medicine & healthMEDICINE GENERAL & INTERNAL11 Medical and Health SciencesKlinik Tıpsurgery; global surgery; health-care systemCovid19NIHR Global Health Unit on Global SurgeryGeneral MedicineHospitalsHospital preparedneTıphealth-care systemElective Surgical ProceduresHEALTH SYSTEMS*PandemicsMedicineFemaleLife Sciences & BiomedicineHumanHälso- och sjukvårdsorganisation hälsopolitik och hälsoekonomiTemel Tıp Bilimleri610 Medicine & healthglobal surgeryGenel TıpCAPACITYCOVIDSurg CollaborativeHospitalMedicine General & InternalGeneral & Internal MedicineHealth SciencesHumansPandemicsScience & TechnologyElective Surgical ProcedurePandemicKirurgiPlanned surgeryCOVID-19Health Care Service and Management Health Policy and Services and Health EconomyCLINICAL MEDICINESettore MED/18Settore MED/18 - Chirurgia Generaleelective surgeryHospital assessmentSystems strengtheningSurgeryHuman medicineMETHODOLOGY[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” S…

2020

: Background: The optimal anti-angiogenic strategy as second-line treatment in RAS wild-type metastatic colorectal cancer (mCRC) treated with anti-EGFR (Epidermal Growth Factor Receptor) based first-line treatment is still debated. Methods: This multicenter, real-world, retrospective study is aimed at evaluating the effectiveness of second-line Bevacizumab- and Aflibercept-based treatments after an anti-EGFR based first-line regimen. Clinical outcomes measured were: objective response rate (ORR), progression free survival (PFS), overall survival (OS) and adverse events (AEs) profiles. Results: From February 2011 to October 2019, 277 consecutive mCRC patients received Bevacizumab-based (228,…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancerAnti-angiogenicCetuximablcsh:RC254-282Article03 medical and health sciences0302 clinical medicineInternal medicinemedicinePanitumumabProgression-free survivalAfliberceptRAS wild-type mCRCPerformance statusCetuximabbusiness.industryPanitumumabanti-angiogenicsmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensBevacizumabRegimen030104 developmental biologyOncology030220 oncology & carcinogenesissecond-line treatmentbusinessAfliberceptaflibercept; anti-angiogenics; bevacizumab; cetuximab; panitumumab; ras wild-type mcrc; second-line treatmentmedicine.drugCancers
researchProduct